Advertisement
Canada markets open in 4 hours 52 minutes
  • S&P/TSX

    22,265.05
    -108.35 (-0.48%)
     
  • S&P 500

    5,306.04
    +1.32 (+0.02%)
     
  • DOW

    38,852.86
    -216.74 (-0.55%)
     
  • CAD/USD

    0.7321
    -0.0008 (-0.11%)
     
  • CRUDE OIL

    80.41
    +0.58 (+0.73%)
     
  • Bitcoin CAD

    92,572.85
    -230.42 (-0.25%)
     
  • CMC Crypto 200

    1,457.98
    -26.71 (-1.80%)
     
  • GOLD FUTURES

    2,347.90
    -8.60 (-0.36%)
     
  • RUSSELL 2000

    2,066.85
    -2.82 (-0.14%)
     
  • 10-Yr Bond

    4.5420
    +0.0750 (+1.68%)
     
  • NASDAQ futures

    18,832.00
    -108.50 (-0.57%)
     
  • VOLATILITY

    14.02
    +1.10 (+8.51%)
     
  • FTSE

    8,236.20
    -17.98 (-0.22%)
     
  • NIKKEI 225

    38,556.87
    -298.50 (-0.77%)
     
  • CAD/EUR

    0.6754
    +0.0007 (+0.10%)
     

4 Reasons Canopy Growth Stock Looks Like a Screaming Buy

edit Jars of marijuana
Image source: Getty Images

Written by Amy Legate-Wolfe at The Motley Fool Canada

It didn’t look possible. And yet, here we are. Shares of Canopy Growth (TSX:WEED) have absolutely surged in the last few weeks. There are macro reasons, but those reasons affect the company more than some of its peers. So, let’s get into them and why Canopy Growth stock could be a screaming buy right now on the TSX today, especially for long-term shareholders.

Reclassification

The most recent hurdle that looks good for the company comes from the United States. The Drug Enforcement Administration (DEA) looks as though it will reclassify marijuana as a less dangerous drug. This has sparked investor optimism for eventual U.S. federal legalization, which could be a massive boon for Canadian cannabis companies like Canopy Growth stock.

ADVERTISEMENT

This reclassification is huge news for the cannabis sector. Removing marijuana from Schedule I (the most dangerous drug classification) would make it easier for researchers to obtain permits to study its potential medical benefits. This could lead to breakthroughs in areas like pain management, epilepsy, and even mental health conditions.

More opportunities

What’s more, federal legalization (which could follow reclassification) would open the massive U.S. market to Canadian cannabis companies like Canopy Growth stock. This could lead to significant revenue growth for the industry. And this would add even more benefits.

Once in a lower schedule, there would be numerous benefits. These include federal taxation and regulation of cannabis, generating tax revenue, and even reducing crime associated with the black market. Furthermore, businesses in the legal cannabis industry have a difficult time banking and attracting investment from federal restrictions. Reclassification could, therefore, ease these limitations.

Canopy Growth’s growth

Then there are the specifics around Canopy Growth stock. Canopy Growth stock is a major player in the Canadian cannabis market, with a large brand presence and established production capabilities. The company has been restructuring to become more profitable, streamlining operations and focusing on high-margin products. Canopy Growth is expanding into new markets like beverages and edibles, which could be significant revenue drivers in the future.

When it comes to the United States, however, Canopy Growth has been making strategic acquisitions in the U.S. market through partnerships like Acreage Holdings, positioning itself for entry if federal legalization occurs. Yet, as mentioned, there are likely to be more benefits for the company even before legalization. Taxes and banking, in particular, could help lead the stock to a profit sooner as opposed to later.

Financing

In the meantime, Canopy Growth stock has been further strengthening its balance sheet. After all, as it’s seen, the company cannot solely depend on a potential new future. Canopy Growth stock, therefore, announced a financing agreement with a single institutional investor, expecting to receive around US$50 million in gross proceeds. The agreement involves exchanging approximately $27.5 million of existing debt for a new senior unsecured convertible debenture maturing in five years.

The investor will acquire a convertible debenture and additional common share purchase warrants, allowing them to acquire common shares at $14.38 for a five-year period. However, the convertible debenture will bear interest at 7.5% and can be converted into common shares automatically should shares hit $21.57.

Bottom line

Canopy Growth stock is growing. The company’s future looks far brighter than it did even just a year ago. While there is still volatility ahead, investors may want to consider opening a stake in the company once more, especially if they plan on holding for years, not just a few months.

The post 4 Reasons Canopy Growth Stock Looks Like a Screaming Buy appeared first on The Motley Fool Canada.

Should you invest $1,000 in Canopy Growth right now?

Before you buy stock in Canopy Growth, consider this:

The Motley Fool Stock Advisor Canada analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Canopy Growth wasn’t one of them. The 10 stocks that made the cut could potentially produce monster returns in the coming years.

Consider MercadoLibre, which we first recommended on January 8, 2014 ... if you invested $1,000 in the “eBay of Latin America” at the time of our recommendation, you’d have $15,578.55!*

Stock Advisor Canada provides investors with an easy-to-follow blueprint for success, including guidance on building a portfolio, regular updates from analysts, and two new stock picks each month – one from Canada and one from the U.S. The Stock Advisor Canada service has outperformed the return of S&P/TSX Composite Index by 32 percentage points since 2013*.

See the 10 stocks * Returns as of 3/20/24

More reading

Fool contributor Amy Legate-Wolfe owns shares of Canopy Growth Corporation. The Motley Fool has a disclosure policy.

2024